Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data
N Levitan, A Dowlati, SC Remick, HI Tahsildar… - Medicine, 1999 - journals.lww.com
Abbreviations used in this article: DRG, Diagnostic Related Group; DVT, deep vein
thrombosis; HCFA, Health Care Financing Administration; ICD-9, International Classification of …
thrombosis; HCFA, Health Care Financing Administration; ICD-9, International Classification of …
A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in …
Combretastatin A-4 phosphate (CA4P) is a novel antitumor vascular targeting agent, the first
agent of this class of compounds to enter the clinic. We performed a Phase I trial to …
agent of this class of compounds to enter the clinic. We performed a Phase I trial to …
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors
…, JA Lindenfeld, G Liu, SC Remick… - Journal of the …, 2010 - academic.oup.com
Hypertension is a mechanism-based toxic effect of drugs that inhibit the vascular endothelial
growth factor signaling pathway (VSP). Substantial evidence exists for managing …
growth factor signaling pathway (VSP). Substantial evidence exists for managing …
[HTML][HTML] Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment
…, A Hossain, CJ Mooney, J Parmentier, SC Remick - Journal of …, 2011 - hindawi.com
Anaplastic thyroid cancer (ATC) is an uncommon malignancy of the thyroid. Only 1-2% of
thyroid cancers are anaplastic, but the disease contributes to 14–50% of the mortality with a …
thyroid cancers are anaplastic, but the disease contributes to 14–50% of the mortality with a …
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma
…, J Von Roenn, BJ Dezube, SC Remick… - Blood, The Journal …, 2010 - ashpublications.org
Rituximab plus intravenous bolus chemotherapy is a standard treatment for immunocompetent
patients with B-cell non-Hodgkin lymphoma (NHL). Some studies have suggested that …
patients with B-cell non-Hodgkin lymphoma (NHL). Some studies have suggested that …
Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid
…, R Chapman, J Wasman, A Dowlati, SC Remick - Thyroid, 2013 - liebertpub.com
Background: Anaplastic thyroid cancer (ATC) is a rare but highly aggressive malignancy with
a median survival of 3–5 months. The BRAF oncogene is mutated to its active form in up to …
a median survival of 3–5 months. The BRAF oncogene is mutated to its active form in up to …
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients
…, O Garcia, M Morgades, SC Remick… - Blood, The Journal …, 2013 - ashpublications.org
Limited comparative data exist for the treatment of HIV-associated non-Hodgkin lymphoma.
We analyzed pooled individual patient data for 1546 patients from 19 prospective clinical …
We analyzed pooled individual patient data for 1546 patients from 19 prospective clinical …
A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome
…, PH Hartman, JD Ortiz, PN Lavertu, SC Remick - Thyroid, 2009 - liebertpub.com
Background: Fosbretabulin is a novel vascular-disrupting agent that has antitumor activity
against anaplastic thyroid cancer (ATC) cell lines, xenografts, and demonstrable efficacy in a …
against anaplastic thyroid cancer (ATC) cell lines, xenografts, and demonstrable efficacy in a …
Extrapulmonary and pulmonary small‐cell carcinoma: tumor biology, therapy, and outcome
SC Remick, JC Ruckdeschel - Medical and pediatric oncology, 1992 - Wiley Online Library
Extrapulmonary small‐cell cancer is a distinct clinicopathological entity from smallcell anaplastic
carcinoma of the lung. Approximately 1,000 cases have been projected annually in the …
carcinoma of the lung. Approximately 1,000 cases have been projected annually in the …
Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma
…, C Lu, SM Karandikar, F Khuri, L Licitra, SC Remick - Thyroid, 2014 - liebertpub.com
Background: Anaplastic thyroid cancer (ATC), a rare highly vascularized tumor, has a
dismal outcome. We conducted an open-label study of doublet carboplatin/paclitaxel …
dismal outcome. We conducted an open-label study of doublet carboplatin/paclitaxel …